DTx Pharma Expands Research & Operations at New Facility in San Diego, California
"We are very excited to be one of the first biotech companies to move into this state-of-the art lab and office space, joining many other important companies in this emerging area," said Arthur T. Suckow, Co-Founder and CEO of DTx Pharma.
"This new facility represents an important strategic step for DTx. It provides us with a solid foundation to grow our culture, expand our team and speed development and deployment of our fatty acid conjugate technology platform to solve the drug delivery challenges associated with RNA-based medicines," he added.
DTx's new facility in Sorrento Valley, which was completed less than a year ago, will allow the company to internalize its chemistry efforts, broaden the application of its fatty acid conjugate technology, and expand its team and infrastructure to support the future growth of the company.
According to company officials, DTx was launched in August 2017 and completed its $10.6M Series A in January 2020 with investment from FBV Fund I, Eli Lilly, Viva Biotech, ExSight Ventures and the Tech Coast Angels, among others. The company's proprietary delivery technology platform utilizes fatty acids as targeting ligands to enable the delivery of oligonucleotide therapies to tissues and cell types throughout the body.
2019 Top States for Doing Business: Georgia Ranks #1 Sixth Year in a Row
2019 Leading Metro Locations: Pacific and South-Atlantic Metros Dominate the List
A Heightened Focus on Reshoring
COVID-19 and Site Selection in the Near and Long Term
Site Selection 2020: The Importance of “Regional Depth” with Global Reach
34th Annual Corporate Survey & the 16th Annual Consultants Survey